← Back to Clinical Trials
Recruiting NCT07612371

NCT07612371 Effects of Motor Imagery and Action Observation on Motor Function in Unilateral Cerebral Palsy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07612371
Status Recruiting
Phase
Sponsor Bahçeşehir University
Condition Cerebral Palsy (CP)
Study Type INTERVENTIONAL
Enrollment 48 participants
Start Date 2026-05-15
Primary Completion 2026-10

Eligibility & Interventions

Sex All sexes
Min Age 7 Years
Max Age 16 Years
Study Type INTERVENTIONAL
Interventions
motor imageryAction observation therapyConventional physiotherapy group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 48 participants in total. It began in 2026-05-15 with a primary completion date of 2026-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to evaluate the effects of action observation therapy and motor imagery methods, provided in addition to a conventional physiotherapy and rehabilitation program, on gross motor function, upper and lower extremity functional skills, and quality of life in children with cerebral palsy.

Eligibility Criteria

Inclusion Criteria: * Being between 7 and 16 years of age * Having a diagnosis of unilateral cerebral palsy made by a pediatric neurologist * Being classified at levels I-II of the Gross Motor Function Classification System (GMFCS) * Scoring above 24 on the Mini-Mental State Examination for Children * Having no cognitive impairments (i.e., possessing an appropriate cognitive level to follow task instructions) * Willingness to participate in the study (child and family) * Being classified at levels I-III of the Manual Ability Classification System (MACS) -Being classified at levels I-III of the Communication Function Classification System (CFCS) - Exclusion Criteria: * Children with uncontrolled seizures * Children who have received motor imagery training or action observation therapy within the last 6 months * Children with contractures * Children with severe visual and/or hearing impairments * Being classified at levels III, IV, or V according to the GMFCS * Scoring below 24 on the Mini-Mental State Examination for Children * Being classified at levels IV-V of the Manual Ability Classification System (MACS) * Having undergone orthopedic surgery or botulinum toxin (Botox) treatment within the last 6 months

Contact & Investigator

Central Contact

Betul Unal

✉ betul.unal1@bahcesehir.edu.tr

📞 +905314070105

Principal Investigator

Hasan K. Alptekin, Prof. Dr.

STUDY CHAIR

Bahçeşehir University

Frequently Asked Questions

Who can join the NCT07612371 clinical trial?

This trial is open to participants of all sexes, aged 7 Years or older, up to 16 Years, studying Cerebral Palsy (CP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07612371 currently recruiting?

Yes, NCT07612371 is actively recruiting participants. Contact the research team at betul.unal1@bahcesehir.edu.tr for enrollment information.

Where is the NCT07612371 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT07612371 clinical trial?

NCT07612371 is sponsored by Bahçeşehir University. The principal investigator is Hasan K. Alptekin, Prof. Dr. at Bahçeşehir University. The trial plans to enroll 48 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology